Cytokinetics (CYTK) announced that the first subject has been dosed in a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 594 in healthy subjects. AMG 594 is a cardiac troponin activator, discovered under a joint research program conducted between Amgen (AMGN) and Cytokinetics. The study is being conducted by Amgen in collaboration with Cytokinetics.
https://thefly.com/landingPageNews.php?id=2866971
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.